Peripheral sTREM2-Related Inflammatory Activity Alterations in Early-Stage Alzheimer's Disease

• Published in: The Journal of immunology (1950) Vol. 208; no. 10; pp. 2283 - 2299
• Main Authors: Weber, Grace E, Khrestian, Maria, Tuason, Elizabeth D, Shao, Yvonne, Pillai, Jagan, Rao, Stephen, Feng, Hao, Zhou, Yadi, Cheng, Feixiong, DeSilva, Tara M, Stauffer, Shaun, Leverenz, James B, Bekris, Lynn M
• Format: Journal Article
• Language: English
• Published: United States 15.05.2022
• Subjects: Alzheimer Disease - genetics; Biomarkers; Humans
• ISSN: 0022-1767; 1550-6606
• DOI: 10.4049/jimmunol.2100771

Alzheimer's disease (AD) has been linked to multiple immune system-related genetic variants. Triggering receptor expressed on myeloid cells 2 (TREM2) genetic variants are risk factors for AD and other neurodegenerative diseases. In addition, soluble TREM2 (sTREM2) isoform is elevated in cerebrospinal fluid in the early stages of AD and is associated with slower cognitive decline in a disease stage-dependent manner. Multiple studies have reported an altered peripheral immune response in AD. However, less is known about the relationship between peripheral sTREM2 and an altered peripheral immune response in AD. The objective of this study was to explore the relationship between human plasma sTREM2 and inflammatory activity in AD. The hypothesis of this exploratory study was that sTREM2-related inflammatory activity differs by AD stage. We observed different patterns of inflammatory activity across AD stages that implicate early-stage alterations in peripheral sTREM2-related inflammatory activity in AD. Notably, fractalkine showed a significant relationship with sTREM2 across different analyses in the control groups that was lost in later AD-related stages with high levels in mild cognitive impairment. Although multiple other inflammatory factors either differed significantly between groups or were significantly correlated with sTREM2 within specific groups, three inflammatory factors (fibroblast growth factor-2, GM-CSF, and IL-1β) are notable because they exhibited both lower levels in AD, compared with mild cognitive impairment, and a change in the relationship with sTREM2. This evidence provides important support to the hypothesis that sTREM2-related inflammatory activity alterations are AD stage specific and provides critical information for therapeutic strategies focused on the immune response.